Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017.

IF 2.5 Q1 Multidisciplinary Epidemiologia e Servicos de Saude Pub Date : 2023-03-01 DOI:10.1590/S2237-96222023000300015

Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes

{"title":"Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017.","authors":"Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes","doi":"10.1590/S2237-96222023000300015","DOIUrl":null,"url":null,"abstract":"Objective: to investigate sociodemographic and clinical characteristics of users of atypical antipsychotics receiving care via the Specialized Component of Pharmaceutical Assistance (Componente Especializado da Assistência Farmacêutica - CEAF), for the treatment of schizophrenia in Brazil, between 2008 and 2017.Methods: this was a retrospective cohort study using records of the authorizations for high complexity procedures retrieved from the Outpatient Information System of the Brazilian National Health System, from all Brazilian states.Results: of the 759,654 users, 50.5% were female, from the Southeast region (60.2%), diagnosed with paranoid schizophrenia (77.6%); it could be seen a higher prevalence of the use of risperidone (63.3%) among children/adolescents; olanzapine (34.0%) in adults; and quetiapine (47.4%) in older adults; about 40% of children/adolescents were in off-label use of antipsychotics according to age; adherence to CEAF was high (82%), and abandonment within six months was 24%.Conclusion: the findings expand knowledge about the sociodemographic and clinical profile of users and highlight the practice of off-label use.","PeriodicalId":51473,"journal":{"name":"Epidemiologia e Servicos de Saude","volume":"32 1","pages":"e2022556"},"PeriodicalIF":2.5000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072313/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e Servicos de Saude","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222023000300015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: to investigate sociodemographic and clinical characteristics of users of atypical antipsychotics receiving care via the Specialized Component of Pharmaceutical Assistance (Componente Especializado da Assistência Farmacêutica - CEAF), for the treatment of schizophrenia in Brazil, between 2008 and 2017.

Methods: this was a retrospective cohort study using records of the authorizations for high complexity procedures retrieved from the Outpatient Information System of the Brazilian National Health System, from all Brazilian states.

Results: of the 759,654 users, 50.5% were female, from the Southeast region (60.2%), diagnosed with paranoid schizophrenia (77.6%); it could be seen a higher prevalence of the use of risperidone (63.3%) among children/adolescents; olanzapine (34.0%) in adults; and quetiapine (47.4%) in older adults; about 40% of children/adolescents were in off-label use of antipsychotics according to age; adherence to CEAF was high (82%), and abandonment within six months was 24%.

Conclusion: the findings expand knowledge about the sociodemographic and clinical profile of users and highlight the practice of off-label use.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

巴西国家卫生系统在精神分裂症治疗中使用非典型抗精神病药物的情况：一项队列研究，2008-2017 年。

目的：调查2008年至2017年期间，巴西通过药物援助专业部分（Componente Especializado da Assistência Farmacêutica-CEAF）接受治疗的非典型抗精神病药物使用者的社会人口学和临床特征，以治疗精神分裂症。方法：这是一项回顾性队列研究，使用的是从巴西国家卫生系统门诊信息系统中检索到的巴西各州高难度手术授权记录。结果显示：在 759 654 名用户中，50.5% 为女性，来自东南部地区（60.2%），被诊断为偏执型精神分裂症（77.6%）；儿童/青少年使用利培酮（63.3%）的比例较高；成人使用奥氮平（34.0%）；老年人使用喹硫平（47.4%）。4%）；根据年龄划分，约 40% 的儿童/青少年在标签外使用抗精神病药物；对 CEAF 的依从性较高（82%），6 个月内放弃使用的比例为 24%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊